methyl 2-chloro-4-(methylamino)-5-nitrobenzoate | 1380836-76-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-chloro-4-(methylamino)-5-nitrobenzoate
• CAS: 1380836-76-9
• 化学式: C₉H₉ClN₂O₄
• 分子量: 244.634
• InChiKey: ILXWMVDVVBUSKT-UHFFFAOYSA-N

物化性质

• 沸点：
  397.3±42.0 °C(Predicted)
• 密度：
  1.434±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-chloro-4-(methylamino)-5-nitrobenzoate 在 盐酸 、 水 、 氢气 、 N,N'-羰基二咪唑 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 6.0h， 生成 6-chloro-1-methyl-N-(5-nitro-1,3-thiazol-2-yl)-2-(trifluoromethyl)-1H-benzimidazole-5-carboxamide
  参考文献：
  名称：

  Synthesis and antiprotozoal activity of nitazoxanide–N-methylbenzimidazole hybrids

  摘要：

  A series of a novel hybrid compounds between nitazoxanide and N-methylbenzimidazole were synthesized starting from the corresponding N-methyl-2-nitroanilines. The new hybrid compounds (1-13) were evaluated in vitro against Giardia intestinalis, Entamoeba histolytica, Trichomonas vaginalis. NTZ, MTZ and ABZ were used as drug standards. Experimental evaluations revealed all of the new compounds (1-13) were active and showed strong activity against the three protozoa, particularly with E. histolytica where the IC50 values ranged between 3 and 69 nM.Overall, compounds 2, 5, 7, 8, 9, 11 and 12 stood out with values lower than 87 nM for all three protozoa, comparatively better than the reference drugs. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.011
• 作为产物：
  描述：

  2-氯-4-氟-5-硝基苯甲酸 在 氯化亚砜 作用下， 以 甲醇 、 水 为溶剂， 反应 5.0h， 生成 methyl 2-chloro-4-(methylamino)-5-nitrobenzoate
  参考文献：
  名称：

  NOVEL COMPOUNDS

  摘要：

  这项发明涉及到式I的化合物，它们作为微粒体前列腺素E2合酶-1（mPGES-1）的抑制剂的用途，含有它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病和相关症状的药物的用途。A、L、M、W、R1、R2、R3、R4、R6、R7、R9、Ra、Rb在描述中有给出含义。

  公开号：

  US20120149676A1

文献信息

• [EN] SUBSTITUTED TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS
  申请人：LUPIN LTD

  公开号：WO2021130731A1

  公开（公告）日：2021-07-01

  Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

  本文披露了一般式（I）的化合物，其互变异构体，立体异构体，药用可接受的盐，其多晶形或溶剂化合物，其中，环A，环B，R1至R4和n如本处定义，用作SOS1抑制剂，用于治疗增生性、感染性和RAS病或障碍。还披露了一种合成一般式I化合物的方法，含有一般式I化合物的制药组合物，治疗增生性、感染性和RAS病或障碍的方法，例如，癌症，通过给予所述化合物和一般式I化合物与其他活性成分的组合。
• [EN] 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS<br/>[FR] DÉRIVÉS DE 6 -AMINO- 2 - PHÉNYLAMINO- 1H-BENZIMIDAZOLE- 5 -CARBOXAMIDE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PROSTAGLANDINE E2 SYNTHASE-1 MICROSOMALE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012076673A1

  公开（公告）日：2012-06-14

  This invention relates to compounds of formula (I) their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, R9, Ra, Rb have meanings given in the description.

  这项发明涉及式(I)的化合物，它们作为微粒体前列腺素E2合酶-1(mPGES-1)的抑制剂的用途，含有它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病和相关症状的药物的用途。A、L、M、W、R1、R2、R3、R4、R6、R7、R9、Ra、Rb在描述中有给定的含义。
• Compounds
  申请人：Priepke Henning

  公开号：US08674113B2

  公开（公告）日：2014-03-18

  This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, R9, Ra, Rb have meanings given in the description.

  本发明涉及公式I的化合物，它们的用途是作为微粒体前列腺素E2合成酶-1（mPGES-1）的抑制剂，包含它们的制药组合物，并将它们用作治疗和/或预防炎症性疾病及相关病症的药物。其中，A、L、M、W、R1、R2、R3、R4、R6、R7、R9、Ra、Rb的含义详见说明。
• 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2649051A1

  公开（公告）日：2013-10-16
• US8674113B2
  申请人：——

  公开号：US8674113B2

  公开（公告）日：2014-03-18